Vimarsana
Biggest News Aggregation in the World

Page 4 - Laboratory Abnormalities News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Laboratory Abnormalities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Laboratory Abnormalities Today - Breaking & Trending Today

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention - Vimarsana News

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology...

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1% - Vimarsana News

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab In RELATIVITY-047, Opdualag more than

Bristol Myers Squibb Announces New Sotyktu&#x2122; (deucravacitinib) Long-Term Data Showing Clinical Effica - Vimarsana News

Bristol Myers Squibb Announces New Sotyktu&#x2122; (deucravacitinib) Long-Term Data Showing Clinical Effica

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...

U.S. Food and Drug Administration Approves Sotyktu&#x2122; (deucravacitinib), Oral Treatment for Adults w - Vimarsana News

U.S. Food and Drug Administration Approves Sotyktu&#x2122; (deucravacitinib), Oral Treatment for Adults w

  Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 yearsPivotal Phase 3 POETYK PSO clinical trials demonstrate...

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer - Vimarsana News

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

05.09.2022 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology (ESMO) Congress ...